☆ 4.5 Review

Seizures in multiple sclerosis

EPILEPSIA (2008)

期刊

EPILEPSIA

卷 49, 期 6, 页码 948-953

出版社

BLACKWELL PUBLISHING

DOI: 10.1111/j.1528-1167.2008.01565.x

关键词

multiple sclerosis; seizure; epilepsy; convulsions; treatment

类别

Clinical Neurology

向作者/读者索取更多资源

Protocol

Reagent

摘要

Seizures have long been recognized to be part of the disease spectrum of multiple sclerosis (MS). While they occur in only a minority of patients with MS, epileptic seizures can have serious consequences. The treatment of MS can be epileptogenic, and antiepileptic treatment can conversely worsen the symptoms of MS. In this article we present an overview of the current literature on the epidemiology, clinical presentation, pathology, imaging, prognosis and treatment of epileptic seizures in MS.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Chemistry, Medicinal

The Cross Talk between Underlying Mechanisms of Multiple Sclerosis and Epilepsy May Provide New Insights for More Efficient Therapies

Atefeh Rayatpour, Sahar Farhangi, Ester Verdaguer, Jordi Olloquequi, Jesus Urena, Carme Auladell, Mohammad Javan

Summary: Despite significant differences in the pathological background of neurodegenerative diseases, epileptic seizures are a common comorbidity in disorders like HD, AD, and MS. Patients with MS have a three to six times higher risk of developing epilepsy compared to the general population. Understanding the pathological processes linking epilepsy and MS may unveil new avenues in managing neurological disorders.

PHARMACEUTICALS (2021)

添加到收藏夹

Article Clinical Neurology

Costs and cost-driving factors of acute treatment of status epilepticus in children and adolescents: A cohort study from Germany

Susanne Schubert-Bast, Clara Lenders, Matthias Kieslich, Felix Rosenow, Adam Strzelczyk

Summary: This study aims to provide data on inpatient costs and cost-driving factors in children and adolescents with status epilepticus. The results show that the treatment of status epilepticus is associated with high hospital costs and prolonged duration. Patients with disabilities are at higher risk for an unfavorable course of status epilepticus.

SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2022)

添加到收藏夹

Article Immunology

The impact of the comorbid seizure/epilepsy on the health related quality of life in people with multiple sclerosis: an international multicentric study

Jelena Drulovic, Tatjana Pekmezovic, Olivera Tamas, Ivan Adamec, Dejan Aleksic, Marko Andabaka, Vanja Basic Kes, Silva Butkovic Soldo, Mirjana Cukic, Livija Despinic, Evica Dincic, Jasminka Djelilovic Vranic, Sanja Grgic, Mario Habek, Sonya Ivanova Hristova, Jovana Ivanovic, Aleksa Jovanovic, Vanja Jovicevic, Magdalena Krbot Skoric, Igor Kuzmanovski, Gorica Maric, Sarlota Mesaros, Ivan Gospodinov Milanov, Svetlana Miletic Drakulic, Osman Sinanovic, Ingrid Skarpa Prpic, Josip Sremec, Daliborka Tadic, Gordana Toncev, Dragoslav Sokic

Summary: The health-related quality of life of people with multiple sclerosis is usually deteriorated, and comorbidities may have a negative influence on the quality of life of these individuals. This study aimed to assess the impact of comorbid seizure/epilepsy on the HRQoL in people with multiple sclerosis.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Clinical Neurology

Stiripentol for Drug-Resistant Epilepsy Treatment in Tuberous Sclerosis Complex

Gewalin Aungaroon, Amar Mehta, Paul S. Horn, David N. Franz

Summary: This study evaluates the efficacy and tolerability of stiripentol (STP) in patients with tuberous sclerosis complex (TSC) and drug-resistant epilepsy (DRE). The results show that approximately 46% of the patients had favorable outcomes, and younger age, early STP treatment, higher doses, and higher baseline seizure frequency were significantly associated with favorable outcomes.

PEDIATRIC NEUROLOGY (2023)

添加到收藏夹

Review Medicine, Research & Experimental

Seizures and multiple sclerosis-more than an epidemiological association (Review)

Dorin Cristian Antal, Thomas Gabriel Schreiner, Theona Eliza Crihan, Bogdan Emilian Ignat, Victoria San Antonio-Arce, Iulian Dan Cuciureanu

Summary: This review discusses the association between epilepsy and multiple sclerosis, covering epidemiological and clinical data, pathophysiological mechanisms, as well as diagnostic and therapeutic directions.

EXPERIMENTAL AND THERAPEUTIC MEDICINE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Thermal laser ablation with tunable lesion size reveals multiple origins of seizure-like convulsions in Caenorhabditis elegans

Anthony D. Fouad, Alice Liu, Angelica Du, Priya D. Bhirgoo, Christopher Fang-Yen

Summary: Laser microsurgery is an important tool for assessing specific cell and tissue functions. A newly developed infrared laser ablation system was used in C. elegans to investigate convulsions caused by lesions in distinct motor circuit subsets. This study revealed that convulsions can independently arise from different subsets of the motor circuit.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Review Clinical Neurology

Utility of serum lactate on differential diagnosis of seizure-like activity: A systematic review and meta-analysis

Jigar Patel, Quincy K. Tran, Santiago Martinez, Halley Wright, Ali Pourmand

Summary: This meta-analysis found that serum lactate levels can be a valuable tool in differentiating generalized tonic-clonic seizures (GTCS) from other forms of transient loss of consciousness (TLOC) in the emergency department.

SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2022)

添加到收藏夹

Review Plant Sciences

Monoterpenes as a perspective for the treatment of seizures: A Systematic Review

Licia T. S. Pina, Adriana G. Guimaraes, Wagner B. da R. Santos, Marlange A. Oliveira, Thallita K. Rabelo, Mairim R. Serafini

Summary: This study reviewed 35 monoterpenes with anticonvulsive activity, which have the potential therapeutic effect on epilepsy by reducing seizure activity through targeting key pharmacological targets and reducing neuronal inflammation and oxidative stress caused by seizures. Monoterpenes may represent a promising alternative treatment option, but further research is needed to determine their mechanism of action and safety assessment.

PHYTOMEDICINE (2021)

添加到收藏夹

Article Health Care Sciences & Services

Changes in the Brain in Temporal Lobe Epilepsy with Unilateral Hippocampal Sclerosis: An Initial Case Series

Sung Chul Lim, Juhee Oh, Bo Young Hong, Seong Hoon Lim

Summary: Temporal lobe epilepsy (TLE) is a network disorder of the brain, characterized by hippocampal dysfunction. This study found significant changes in the volumes of the amygdala, hippocampus, and thalamus in patients with left TLE and hippocampal sclerosis (HS), while no abnormal diffusion properties associated with volume reduction were found in specific brain regions of patients with right TLE and HS.

HEALTHCARE (2022)

添加到收藏夹

Article Clinical Neurology

Markov modelling of treatment response in a 30-year cohort study of newly diagnosed epilepsy

Hugh D. Simpson, Emma Foster, Zanfina Ademi, Nicholas Lawn, Martin J. Brodie, Zhibin Chen, Patrick Kwan

Summary: This study developed a Markov model to predict the probability of future seizure-freedom in people with epilepsy based on current seizure state and number of antiseizure medication regimens trialled. The study found that once seizure-freedom was achieved, it was likely to persist regardless of the number of medications tried. Risk tables were constructed to individualize the prediction of future seizure control trajectory.

BRAIN (2022)

添加到收藏夹

Review Oncology

Meningioma Related Epilepsy- Pathophysiology, Pre/postoperative Seizures Predicators and Treatment

Rasha Elbadry Ahmed, Hailiang Tang, Anthony Asemota, Lei Huang, Warren Boling, Firas Bannout

Summary: Meningiomas are common primary brain tumors, with surgery being the main treatment method, but some patients continue to experience seizures post-operatively. Understanding pre- and post-operative predictors is important for guiding more effective seizure control.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Long-Term Seizure Freedom, Resolution of Epilepsy and Perceived Life Changes in Drug Resistant Temporal Lobe Epilepsy With Hippocampal Sclerosis: Comparison of Surgical Versus Medical Management

Sita Jayalakshmi, Sindhu Vasireddy, Jala Sireesha, Sudhindra Vooturi, Anuja Patil, Sai Sirisha, Rammohan Vadapalli, Y. B. V. K. Chandrasekhar, Manas Panigrahi

Summary: This study compared the long-term outcomes of surgery vs best medical management in patients with drug-resistant temporal lobe epilepsy associated with hippocampal sclerosis. The results showed that surgery was associated with higher rates of seizure freedom, resolution of epilepsy, and improvement in perceived life changes.

NEUROSURGERY (2023)

添加到收藏夹

Article Clinical Neurology

Early identification of seizure freedom with medical treatment in patients with mesial temporal lobe epilepsy and hippocampal sclerosis

Margaux Cheval, Marion Houot, Nathalie Chastan, William Szurhaj, Cecile Marchal, Helene Catenoix, Luc Valton, Martine Gavaret, Bastien Herlin, Arnaud Biraben, Stanislas Lagarde, Laure Mazzola, Lorella Minotti, Louis Maillard, Sophie Dupont

Summary: This study investigated the clinical factors associated with seizure freedom in medically treated MTLE-HS patients and developed a machine-learning classifier to identify these patients earlier. The results showed that these seizure-free patients had different clinical characteristics compared to drug-resistant MTLE-HS patients. The classifier built with clinical data accurately identified these patients, which could individualize the management of MTLE-HS patients according to their expected pharmacosensitivity.

JOURNAL OF NEUROLOGY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Comparative antiseizure medications of adjunctive treatment for children with drug-resistant focal-onset seizures: A systematic review and network meta-analysis

Lanlan Zhang, Yuehong Li, Weikai Wang, Chengzhong Wang

Summary: This study aimed to compare and rank the efficacy and tolerability of antiseizure medications for adjunctive treatment of drug-resistant focal-onset seizures in children. The results indicated that lamotrigine and levetiracetam were more effective, while oxcarbazepine had poorer tolerability.

FRONTIERS IN PHARMACOLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial

Joseph Sullivan, Lieven Lagae, J. Helen Cross, Orrin Devinsky, Renzo G. Guerrini, Kelly Knupp, Linda Laux, Marina Nikanorova, Tilman Polster, Dinesh Talwar, Berten Ceulemans, Rima M. Nabbout, Gail S. Farfel, Bradley R. Galer, Arnold Gammaitoni, Michael Lock, Anupam E. Agarwal, Ingrid Scheffer, FAiRE DS Study Grp

Summary: This study examined the safety and effectiveness of fenfluramine in treating convulsive seizures in patients with Dravet syndrome. The results showed that patients treated with fenfluramine had lower seizure frequency and longer interval between seizures compared to the placebo group. Common side effects of fenfluramine were observed, but no evidence of severe cardiac or vascular issues was found.

EPILEPSIA (2023)

添加到收藏夹

Article Clinical Neurology

Repurposing Domperidone in Secondary Progressive Multiple Sclerosis A Simon 2-Stage Phase 2 Futility Trial

Marcus W. Koch, Kayla Sage, Sharanjit Kaur, Janet Kim, Graziela Cerchiaro, V. Wee Yong, Gary R. Cutter, Luanne M. Metz

Summary: In this phase 2 futility trial, treatment with the generic drug domperidone did not show efficacy in reducing disability progression in secondary progressive multiple sclerosis (SPMS). Patients with higher prolactin levels during the study had a significantly lower risk of disability progression, indicating a potential avenue for further investigation.

NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset

Marcus W. Koch, Jop Mostert, Pavle Repovic, James D. Bowen, Eva Strijbis, Bernard Uitdehaag, Gary Cutter

Summary: In primary progressive MS (PPMS) patients, smoking was found to be associated with disability worsening, while obesity showed no significant correlation. Over three years of follow-up, smoking and BMI were not linked to physical and cognitive disability worsening risk.

JOURNAL OF NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis

Marcus W. Koch, Jop Mostert, Pavle Repovic, James D. Bowen, Eva Strijbis, Bernard Uitdehaag, Gary Cutter

Summary: The study investigated the association between MRI outcomes and physical and cognitive disability worsening in people with SPMS using data from the ASCEND trial. Results showed that while there was no association between MRI measures and EDSS or SDMT worsening, worsening in T25FW and NHPT was associated with specific MRI outcomes. The study concluded that standard MRI outcomes may not be useful surrogates of disability measures in SPMS.

MULTIPLE SCLEROSIS JOURNAL (2022)

添加到收藏夹

Article Clinical Neurology

Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis

Marcus W. Koch, Jop Mostert, Pavle Repovic, James D. Bowen, Jerry S. Wolinsky, Fred D. Lublin, Eva Strijbis, Gary Cutter

Summary: This study investigated the risk factors associated with early treatment failure in RRMS and found that early treatment failure was related to NEDA-3 failure at 36 months, but not to subsequent disability worsening. The majority of NEDA-3 failures were due to MRI activity. Further research into defining treatment success and failure in RRMS is necessary.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS

Marcus W. Koch, Jop Mostert, Pavle Repovic, James D. Bowen, Eva Strijbis, Bernard Uitdehaag, Gary Cutter

Summary: HRQOL measures were most associated with EDSS and T25FW, less so with NHPT and SDMT, and not associated with lesional and volumetric imaging outcomes.

MULTIPLE SCLEROSIS JOURNAL (2022)

添加到收藏夹

Editorial Material Clinical Neurology

Multiple Sclerosis Diagnostic Criteria Moving Ahead or Walking in Place?

Gary R. Cutter, Marcus W. Koch

NEUROLOGY (2022)

添加到收藏夹

Article Immunology

Serum HGF and APN2 are associated with disability worsening in SPMS

Isabelle Tottenham, Marcus Koch, Carlos Camara-Lemarroy

Summary: This study analyzed circulating biomarkers of hypoxia and angiogenesis in patients with Secondary Progressive MS (SPMS) and found that concentrations of glucose transporter-1 (Glut-1) were higher, while levels of angiopoietin-2 (APN2) and hepatocyte growth factor (HGF) were lower, in SPMS patients with disability worsening.

JOURNAL OF NEUROIMMUNOLOGY (2022)

添加到收藏夹

Article Clinical Neurology

The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset

Marcus W. Koch, Jop Mostert, Pavle Repovic, James D. Bowen, Jacynthe Comtois, Eva Strijbis, Bernard Uitdehaag, Gary Cutter

Summary: This study found that using timed 25-foot walk (T25FW) as the primary outcome measure might be more useful than the Expanded Disability Status Scale (EDSS) in clinical trials for primary progressive MS (PPMS), and using T25FW could shorten the duration of clinical trials. Additionally, the presence of contrast-enhancing lesions (CELs) at baseline was associated with disability outcomes.

JOURNAL OF NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials

Eva M. M. Strijbis, Pavle Repovic, Jop Mostert, James D. Bowen, Bernard M. J. Uitdehaag, Gary Cutter, Marcus W. Koch

Summary: This study investigated the performance of patient-reported outcome measures (PROMs) as longitudinal outcomes in individuals with secondary progressive multiple sclerosis (SPMS). The results showed minimal changes in PROM scores over the 2-year follow-up period, with no consistent trend in improvement or worsening. These findings suggest caution in using PROMs as primary outcome measures in SPMS trials.

MULTIPLE SCLEROSIS JOURNAL (2022)

添加到收藏夹

Article Clinical Neurology

Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis

Carlos Camara-Lemarroy, Claudia Silva, Jit Gohill, V. Wee Yong, Marcus Koch

Summary: In this cohort of patients with inactive PPMS, HCQ treatment attenuated the increase of NfL and GFAP after 6 months of treatment and up to 18 months of follow-up, suggesting a treatment effect of HCQ over these biomarkers. RNFL thickness, a marker of neuroaxonal atrophy, was associated with disability worsening and should be explored further as a prognostic marker in this population.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

添加到收藏夹

Article Clinical Neurology

The nine hole peg test as an outcome measure in progressive MS trials

Marcus W. Koch, Pavle Repovic, Jop Mostert, James D. Bowen, Jacynthe Comtois, Eva Strijbis, Bernard Uitdehaag, Gary Cutter

Summary: This study used patient-level data from two large randomized controlled trials to investigate the performance of alternative scoring methods for the nine-hole peg test (NHPT) in progressive multiple sclerosis (MS). The results showed that the standard NHPT and dominant hand (DH) or non-dominant hand (NDH) alternatives had minimal change, while the NHPT using either hand (EH) resulted in more worsening events. Non-ambulatory patients with progressive MS had more NHPT worsening, especially when using the EH NHPT. Therefore, NHPT can be used as the primary outcome measure in clinical trials involving non-ambulatory patients, but further research is needed to assess its precision in this population.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

添加到收藏夹

Article Clinical Neurology

Threshold definitions for significant change on the timed 25-foot walk and nine-hole peg test in primary progressive multiple sclerosis

Marcus W. Koch, Pavle Repovic, Jop Mostert, James D. Bowen, Jacynthe Comtois, Eva Strijbis, Bernard Uitdehaag, Gary Cutter

Summary: This study investigates the short-term variation in T25FW and NHPT using patient-level original trial data and compares it with disability change at 12-month follow-up in people with PPMS. The traditional =20% change threshold for T25FW and NHPT represents a reasonable compromise between reducing false change events and achieving a large number of change events during follow-up.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

添加到收藏夹

Article Clinical Neurology

Association between age and inflammatory disease activity on magnetic resonance imaging in relapse onset multiple sclerosis during long-term follow-up

Eline Coerver, Sophie Janssens, Aroosa Ahmed, Mark Wessels, Zoe van Kempen, Bas Jasperse, Frederik Barkhof, Marcus Koch, Jop Mostert, Bernard Uitdehaag, Joep Killestein, Eva Strijbis

Summary: Inflammatory disease activity in multiple sclerosis (MS) decreases with advancing age, and this study investigated the relation between age and MRI measures of inflammatory disease activity in a real-world cohort of people with relapse onset MS.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

添加到收藏夹

Article Clinical Neurology

Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing-Remitting Multiple Sclerosis An Analysis of the DECIDE Dataset

Nina Castrogiovanni, Jop Mostert, Pavle Repovic, James D. D. Bowen, Bernard M. J. Uitdehaag, Eva M. M. Strijbis, Gary R. R. Cutter, Marcus W. W. Koch

Summary: This study used data from a large clinical trial to describe the change in Symbol Digit Modalities Test (SDMT) and Paced Auditory Serial Addition Test (PASAT) over up to 144 weeks of follow-up. The findings showed that both SDMT and PASAT scores steadily improved throughout the follow-up period, most likely due to a practice effect. Therefore, caution should be exercised when interpreting these cognitive outcome measures as longitudinal outcomes in clinical trials.

NEUROLOGY (2023)

添加到收藏夹

Meeting Abstract Clinical Neurology

Hydroxychloroquine Modifies Angiogenesis Factors in Primary Progressive Multiple Sclerosis

H. Yong, I. E. Tottenham, C. Silva, M. W. Koch, C. Camara-Lemarroy

MULTIPLE SCLEROSIS JOURNAL (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.